Ascendis Pharma A/S (NASDAQ:ASND) Price Target Lowered to $170.00 at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND) had its price objective cut by Cantor Fitzgerald from $173.00 to $170.00 in a report issued on Wednesday morning, Benzinga reports. They currently have an overweight rating on the biotechnology company’s stock.

ASND has been the topic of a number of other reports. Jefferies Financial Group lifted their price target on Ascendis Pharma A/S from $174.00 to $196.00 and gave the company a buy rating in a research note on Tuesday, August 13th. StockNews.com cut shares of Ascendis Pharma A/S from a hold rating to a sell rating in a research note on Tuesday, August 13th. JPMorgan Chase & Co. raised their price objective on shares of Ascendis Pharma A/S from $170.00 to $174.00 and gave the company an overweight rating in a research note on Wednesday, August 21st. Morgan Stanley upped their target price on shares of Ascendis Pharma A/S from $116.00 to $140.00 and gave the stock an equal weight rating in a research report on Thursday, May 16th. Finally, Evercore ISI raised shares of Ascendis Pharma A/S to a strong-buy rating in a report on Monday, August 26th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S has an average rating of Moderate Buy and a consensus target price of $188.09.

Ascendis Pharma A/S Trading Down 11.3 %

Shares of ASND opened at $119.50 on Wednesday. The stock’s 50 day moving average is $135.06 and its two-hundred day moving average is $138.60. Ascendis Pharma A/S has a twelve month low of $85.29 and a twelve month high of $161.00. The firm has a market capitalization of $6.96 billion, a PE ratio of -12.43 and a beta of 0.63.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Quarry LP lifted its position in shares of Ascendis Pharma A/S by 257.1% during the second quarter. Quarry LP now owns 2,500 shares of the biotechnology company’s stock worth $341,000 after purchasing an additional 1,800 shares in the last quarter. Algert Global LLC increased its stake in Ascendis Pharma A/S by 54.6% during the 2nd quarter. Algert Global LLC now owns 2,180 shares of the biotechnology company’s stock worth $297,000 after buying an additional 770 shares during the period. Lighthouse Investment Partners LLC acquired a new position in Ascendis Pharma A/S in the 2nd quarter worth $2,762,000. Fred Alger Management LLC boosted its position in Ascendis Pharma A/S by 65.0% in the 2nd quarter. Fred Alger Management LLC now owns 307,073 shares of the biotechnology company’s stock valued at $41,879,000 after buying an additional 120,952 shares during the last quarter. Finally, First Light Asset Management LLC purchased a new position in Ascendis Pharma A/S in the 2nd quarter valued at about $4,931,000.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.